Approximately 50% of children with functional constipation (FC) or irritable bowel syndrome (IBS) remain symptomatic with conventional treatment.

Linaclotide is a guanylate cyclase-C receptor agonist and may be beneficial for some children with FC (45%) and IBS with constipation (42%).

Adverse events, especially diarrhea, are common and led to discontinuation of linaclotide in nearly a third of children.